Sign In
Buy SRDX
$42.98
+0 (+0%)
At Close: Feb 24, 2026
SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates
09:54am, Wednesday, 26'th Apr 2023
SurModics (SRDX) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.22 per share a year ago.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
12:14pm, Thursday, 06'th Apr 2023
Investors continue to feel optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Surmodics (SRDX) Gets FDA's Formal Feedback About SurVeil DCB
09:59am, Wednesday, 29'th Mar 2023
Surmodics' (SRDX) receipt of the FDA's positive formal feedback regarding its PMA application for the SurVeil DCB looks promising.
SurModics (SRDX) Moves 5.4% Higher: Will This Strength Last?
09:58am, Friday, 17'th Mar 2023
SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in
Surmodics (SRDX) Q1 Earnings Top Estimates, FY23 View Revised
11:18am, Tuesday, 07'th Feb 2023
Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust Medical Device revenues.
Surmodics, Inc. (SRDX) Q1 2023 Earnings Call Transcript
09:41pm, Monday, 06'th Feb 2023
Surmodics, Inc. (NASDAQ:SRDX ) Q1 2023 Earnings Conference Call February 6, 2023 5:00 PM ET Company Representatives Gary Maharaj - President, Chief Executive Officer Tim Arens - Chief Financial Office
SurModics (SRDX) Reports Q1 Loss, Tops Revenue Estimates
07:34pm, Monday, 06'th Feb 2023
SurModics (SRDX) delivered earnings and revenue surprises of 21.88% and 3.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6
08:30am, Thursday, 26'th Jan 2023
EDEN PRAIRIE, Minn.--( BUSINESS WIRE )--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first
SurModics (SRDX) Surges 6.1%: Is This an Indication of Further Gains?
09:02am, Tuesday, 24'th Jan 2023
SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i
Surmodics, Inc. (SRDX) Q4 2022 Earnings Call Transcript
08:45pm, Saturday, 12'th Nov 2022
Surmodics, Inc. (NASDAQ:SRDX ) Q4 2022 Earnings Conference Call November 9, 2022 10:00 AM ET Company Participants Gary Maharaj - CEO, President & Director Timothy Arens - SVP, Finance & Information Te
Surmodics (SRDX) Q4 Earnings and Revenues Top Estimates
09:47am, Thursday, 10'th Nov 2022
Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust Medical Device revenues.
Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th
07:30am, Friday, 28'th Oct 2022
EDEN PRAIRIE, Minn.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
12:47pm, Tuesday, 27'th Sep 2022
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now
03:48pm, Wednesday, 24'th Aug 2022
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Surmodics (SRDX) Beats on Q3 Earnings, Revises FY22 View
02:27pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. However, the company expects softer demand for its products and services in the second half of 2022.
